Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000733470 | SCV000861544 | uncertain significance | not provided | 2018-05-29 | criteria provided, single submitter | clinical testing | |
Invitae | RCV003117535 | SCV003788458 | uncertain significance | Hyperphosphatasia with intellectual disability syndrome 2 | 2022-06-22 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 841 of the PIGO protein (p.Thr841Ile). This variant is present in population databases (rs371089504, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with PIGO-related conditions. ClinVar contains an entry for this variant (Variation ID: 597375). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004027064 | SCV005005612 | uncertain significance | Inborn genetic diseases | 2024-02-28 | criteria provided, single submitter | clinical testing | The c.2522C>T (p.T841I) alteration is located in exon 7 (coding exon 6) of the PIGO gene. This alteration results from a C to T substitution at nucleotide position 2522, causing the threonine (T) at amino acid position 841 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |